MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.37 6.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.27

Max

1.37

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+55.04% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-22M 152M
Eelmine avamishind	-4.83
Eelmine sulgemishind	1.37

Uudiste sentiment

By Acuity

15%

85%

22 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First Quarter Net Rose On Strong Demand

15. apr 2026, 17:13 UTC

Suurimad hinnamuutused turgudel

Tesla Shares Rise on Completion of AI5 Chip Design Process

15. apr 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15. apr 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15. apr 2026, 22:41 UTC

Tulu

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15. apr 2026, 22:38 UTC

Tulu

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15. apr 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. apr 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15. apr 2026, 22:14 UTC

Tulu

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15. apr 2026, 22:12 UTC

Tulu

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology Swings to Loss in 1Q>300433.SZ

15. apr 2026, 22:07 UTC

Tulu

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15. apr 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15. apr 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15. apr 2026, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. apr 2026, 20:30 UTC

Tulu

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. apr 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15. apr 2026, 19:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15. apr 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15. apr 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15. apr 2026, 18:58 UTC

Market Talk

Uudisväärsed sündmused

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15. apr 2026, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15. apr 2026, 17:45 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15. apr 2026, 16:58 UTC

Tulu

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15. apr 2026, 16:52 UTC

Tulu

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15. apr 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15. apr 2026, 16:37 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

55.04% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 55.04%

Kõrge 2 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

22 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.